人乳腺癌原代培养体外药敏试验研究doc-乳腺癌是女性最常.docx

编号：时间：2021年x月x日书山有路勤为径，学海无涯苦作舟页码：第页共NUMPAGES9页第PAGE\*MERGEFORMAT9页共NUMPAGES\*MERGEFORMAT9页·论著·人乳腺癌原代培养体外药敏试验研究100021北京中国医学科学院肿瘤医院肿瘤所生物检测中心李艳芬，田海梅，陈国际2，曹冬艳，刘毅，李茉，王小兵，刘朝阳，梁智，程冬婉，张伟1[摘要]目的:探讨用ATP生物荧光肿瘤体外药敏检测技术（ATP-TCA）研究乳腺癌药敏的异质性和个体化疗的可行性。方法:用ATP-TCA检测114例乳腺癌标本对13种单药或联合用药的敏感性。结果:个体之间的药物敏感性存在着明显的异质性。单药中最有效的药物为紫杉醇、长春瑞滨、表阿霉素、丝裂霉素和阿霉素，分别有73.3％、64.1％、62.3％、49.9％和40.0％的标本对其敏感。联合用药（紫杉醇＋表阿霉素，环磷酰胺＋表阿霉素＋氟尿嘧啶）的敏感率高于单药。结论：乳腺癌对抗癌药物的敏感程度存在着异质性。ATP生物荧光肿瘤药敏检测技术可用于为乳腺癌选择合适的化疗药物。[关键词]ATP生物荧光肿瘤药敏检测技术；乳腺癌；化疗药物敏感性中图分类号：R737.9文献标识码：A文章编号：1009-0460(2006)00-0000-00EvaluationofchemosensitivityofhumanbreastcancerdeterminedbyprimarycultureassayinvitroLIYan-fen,TIANHai-mei,CHENGuo-ji,CAODong-yan,LIUYi,LIMo,WANGXiao-bing,LIUZhao-yang,LIANGZhi,CHENGDong-wan,ZHANGWei.TumorMarkerResearchCenter,CancerHospital/Institute,ChineseAcademyofMedicalSciences,PekingUnionMedicalCollege,Beijing100021,ChinaCorrespondingauther:ZHANGWei,E-mail:HYPERLINK"mailto:[e-mail]"[e-mail][Abstract]ObjectiveToinvestigatetheheterogeneityofchemosensitivityinbreastcancerusinganATP-tumorchemosensitivityassay(ATP-TCA)andthefeasibilityofindividualchemotherapy.MethodsAnATP-TCAwasusedtodeterminetheeffectof13singleorcombinedcytotoxicdrugsinsurgicalspecimensfrom114patientswithbreastcancercancer.ResultsTherewereconsiderabledifferencesinchemosensitivitybetweenindividuals.ThemostactivesingledrugintheassaywasidentifiedasPaclitaxel,Navelbine,Epirubicin,Mitomycinandadriamycin,73.3%,64.1%,62.3%,49.9%and40.0%ofspecimensshowedsensitivitytothem,respectively.Combinationofchemotherapy(Paclitaxel+Epirubicin,Cyclophosphamide+Epirubicin+5-Fluorouracil)wasfoundtobemoreeffectivethanrelativedrugsalone.ConclusionsTherewastheheterogeneityoftheinvitrochemosensitivityinbreastcancer.The